Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

22 December 2020

KN035 (Envafolimab) BLA accepted by the National Medical Products Administration We look forward to the early approval of KN035 for marketing, benefiting more patients and their families.
10 December 2020

Worldwide First-in-class Subcutaneous PD-L1 antibody Envafolimab（KN035）achieved First Patient dose in the US Registration Trial The completion of the first patient dose in the US registration study witnesses another important milestone in the global footprint of KN035 development.
09 December 2020

Alphamab Oncology Announced First Patient dosed in SEARCH-01 – A Potential Pivotal PhaseⅡClinical Trial of KN026 in combination with KN046 for HER2-positive solid tumors We look forward the positiveoutcome of the trial, and bringing significant survival benefits to patients with HER2-positive tumors.
30 November 2020

Alphamab Oncology is elected as one of “2020 Chinese Pharmaceutical Innovative Enterprises 100” Alphamab Oncology was selected for two consecutive years, demonstrating the company's innovative strength to lead the industry.
30 November 2020

Alphamab Oncology is elected as one of “2020 China Top 500 New Economy” Alphamab Oncology will make greater contributions to the high-quality development of China's economy.
16 November 2020

BLA submitted for KN035 (Envafolimab)-The World’s First Subcutaneous PD-L1 Antibody we will continue to develop more safe, effective and globally competitive innovative drugs.
10 November 2020

Alphamab Oncology Presents Clinical Data from Phase Ib Trial of the Combination Therapy of KN026 plus KN046 at the SITC 2020 The combination may offer chemo-free option for patients with HER2-positive solid tumors in the first line or even earlier setting.
26 September 2020

Alphamab Oncology Announced First Patient dosed in ENREACH-LUNG-01 - a pivotal Phase Ⅲ Clinical Trial of PD-L1/CTLA-4 bispecific antibody KN046 in combination with Chemotherapy for the Treatment of Non-small Cell Lung Cancer We hope this phase Ⅲ trial will establish a new standard of care for the first-line treatment of lung cancer.
03 September 2020

Alphamab Oncology announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KN046 for the treatment of thymic epithelial tumor This is the second ODD awarded to Alphamab Oncology by FDA after the first ODD awarded to the subcutaneous PD-L1 antibody KN035 by FDA for the treatment of Biliary track cancer early this year.
02 September 2020

Alphamab Oncology Initiates Phase II Registration Clinical Trial （KN046-205） for bispecific antibody KN046 with a Successful Researchers’ Conference The project is very important to the company's international strategic positioning.

16 17 18 19 20 21 22